Handelsbanken Fonder AB Has $90.54 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Handelsbanken Fonder AB boosted its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 0.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,484,527 shares of the biopharmaceutical company's stock after purchasing an additional 6,956 shares during the quarter. Handelsbanken Fonder AB owned approximately 0.07% of Bristol-Myers Squibb worth $90,541,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Wealthspire Advisors LLC lifted its stake in shares of Bristol-Myers Squibb by 0.6% in the fourth quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock worth $1,622,000 after buying an additional 170 shares in the last quarter. Edmp Inc. raised its position in Bristol-Myers Squibb by 0.4% in the fourth quarter. Edmp Inc. now owns 41,599 shares of the biopharmaceutical company's stock valued at $2,353,000 after purchasing an additional 171 shares during the period. Bedel Financial Consulting Inc. lifted its position in Bristol-Myers Squibb by 3.2% in the fourth quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company's stock valued at $340,000 after buying an additional 175 shares during the last quarter. King Wealth Management Group boosted its position in shares of Bristol-Myers Squibb by 2.6% during the 4th quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company's stock worth $413,000 after purchasing an additional 182 shares during the period. Finally, Signet Investment Advisory Group Inc. grew its position in Bristol-Myers Squibb by 2.3% in the 4th quarter. Signet Investment Advisory Group Inc. now owns 8,261 shares of the biopharmaceutical company's stock valued at $467,000 after acquiring an additional 189 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of Bristol-Myers Squibb stock in a transaction on Friday, April 25th. The stock was bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares of the company's stock, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.09% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on BMY. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $55.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Wall Street Zen lowered shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. UBS Group dropped their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Jefferies Financial Group cut their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb has an average rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Stock Down 1.9%

Shares of NYSE:BMY traded down $0.99 during midday trading on Friday, hitting $49.71. 9,394,854 shares of the company's stock traded hands, compared to its average volume of 13,000,634. The firm's fifty day moving average price is $48.71 and its two-hundred day moving average price is $54.77. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a market cap of $101.15 billion, a PE ratio of -11.25, a P/E/G ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same quarter in the previous year, the business posted ($4.40) EPS. The firm's revenue was down 5.6% compared to the same quarter last year. On average, equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.